Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adaptive Biotechnologies Corp

10.75
+0.09000.84%
Post-market: 10.750.00000.00%19:09 EDT
Volume:1.39M
Turnover:14.89M
Market Cap:1.63B
PE:-11.21
High:10.85
Open:10.73
Low:10.54
Close:10.66
Loading ...

Adaptive Biotechnologies Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St.
·
13 Feb

Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade

Zacks
·
13 Feb

Q4 2024 Adaptive Biotechnologies Corp Earnings Call

Thomson Reuters StreetEvents
·
12 Feb

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

Zacks
·
12 Feb

U.S. RESEARCH ROUNDUP-Edison International, Onestream, Vertex Pharmaceuticals

Reuters
·
12 Feb

Adaptive Biotechnologies Corp (ADPT) Q4 2024 Earnings Call Highlights: Strong MRD Revenue ...

GuruFocus.com
·
12 Feb

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Springworks Therapeutics (SWTX)

TIPRANKS
·
12 Feb

Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks
·
12 Feb

Adaptive Biotechnologies Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
12 Feb

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
12 Feb

Adaptive Biotechnologies' Q4 Loss Narrows, Revenue Rises

MT Newswires Live
·
12 Feb

Adaptive Biotechnologies: Q4 Earnings Snapshot

Associated Press Finance
·
12 Feb

Adaptive Biotechnologies Q4 2024 GAAP EPS $(0.23) Beats $(0.26) Estimate, Sales $47.459M Beat $46.034M Estimate

Benzinga
·
12 Feb

BRIEF-Adaptive Biotechnologies Q4 EPS USD -0.23

Reuters
·
12 Feb

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
12 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
10 Feb

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

GlobeNewswire
·
06 Feb

The 5.4% return this week takes Adaptive Biotechnologies' (NASDAQ:ADPT) shareholders one-year gains to 99%

Simply Wall St.
·
29 Jan

Adaptive Biotechnologies Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
28 Jan